SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to its collaboration with wisesat.space/ to test post-quantum communication from space, generating excitement and high trading volume. The community is actively discussing potential price targets and a possible short squeeze, driven by bullish sentiment and anticipation of future growth. Traders are closely watching for breakouts and potential dips, with long-term investors remaining confident in the company's prospects.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending due to Novo Nordisk's acquisition of their rare disease drug, potentially worth up to $2.1 billion, leading to community excitement and discussions of a possible short squeeze.  The deal is viewed by some as validation of Omeros' pipeline, sparking speculation about a potential buyout, while others are focused on the high short interest and the possibility of further gains.  Community members are actively discussing potential price targets and the overall impact of the news.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone ($VERI) is trending after announcing new contract wins for its VDR (Veritone Data Refinery) product, with hyperscalers and venture-backed AI model developers. The community is bullish on the company's potential to transform unstructured data into license-ready datasets for AI training. Some see this as a major catalyst, anticipating significant growth and comparing VERI to other high-growth AI stocks.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending due to increased interest in agriculture and oilseed stocks, possibly fueled by political factors impacting cooking oil supply chains. The stock's low float and recent reverse split are contributing to volatility, with community members debating its potential for a short squeeze and significant upward movement. Some investors express concerns about the company's management and past performance, while others remain optimistic about potential catalysts like the restaurant sale and crypto treasury strategy.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trending as community members discuss its potential in the nuclear energy sector, particularly in comparison to peers like Oklo. Some traders are noting its technical setup for a potential breakout, while others point to factors like short interest and potential dilution. Discussions also mention NuScale's partnerships and advancements in SMR technology as potential catalysts.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB Construction is trending due to a recently announced $44 million private placement, sparking discussions about the company's financial future and potential for a squeeze. Community members are actively monitoring key price levels and speculating on whether the increased capital will fuel further growth or lead to dilution. The stock's low float and recent momentum have further intensified interest.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending as traders discuss its massive short interest and potential for a squeeze, with some highlighting the upcoming conference in Dubai as a possible catalyst. Bullish sentiment is fueled by its AI-driven drug discovery platform and notable investors like Nvidia. Community members are closely watching key technical levels, anticipating a breakout.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending due to news surrounding AI infrastructure investments and its role as a key supplier for major players like Nvidia and AMD. Community discussions are centered on the potential impact of increased AI demand and upcoming earnings reports. Broader trends in the semiconductor sector, including geopolitical factors and partnerships, are also influencing the stock's movement.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to a recently announced repeat purchase order from a leading UAS manufacturer, signaling strong demand for their SiCore batteries in the drone market. The community is optimistic about the company's growth and potential partnerships, especially within the defense and AI sectors. Discussions also include the company's competitive position, manufacturing costs, and expansion plans.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is trending as chatter increases around its potential for significant growth and status as a national security asset, with community members noting its low float and progress in EU revenues. Many believe the stock is undervalued, and Q3 earnings could be a major catalyst. Some are eyeing a potential short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo Therapeutics shares rose to an 11-month high on Tuesday following a series of analyst upgrades that have rekindled investor interest in the biotech’s gene therapy LX2006 for heart problems associated with Friedreich’s ataxia.The rally came after Lexeo said the U.S. Food and Drug Administration has expressed willingness to consider an accelerated approval pathway for LX2006. Such a move would allow Lexeo to combine data from its current early-stage studies with results from an ongoing pivotal trial, potentially reducing the time to commercialization.Leerink Partners lifted the firm’s price target to $20 from $9 and reiterated an 'Outperform' rating, noting that the FDA’s willingness to pool data from the ongoing Phase I/II SUNRISE-FA and pivotal studies represents “regulatory flexibility and a relatively straightforward path to approval.”&nbsp;The brokerage stated that the FDA’s decision to assess the left ventricular mass index (LVMI), the therapy’s key cardiac endpoint, earlier than planned could accelerate timelines. Additionally, further clinical data show dose-dependent, durable LVMI reductions and clean safety profiles.H.C. Wainwright raised its price target to $15 from $9 and maintained a 'Buy' rating, saying the FDA feedback improves the probability of approval to 50% from 40%. The firm also advanced its expected commercial launch to 2028 from 2030, pointing to a faster and smaller pivotal trial.Chardan followed with an increase to $17 from $15, also keeping a 'Buy' rating. The firm stated that the FDA’s decision to allow the pooling of Phase I/II and pivotal data supports the potential for accelerated approval, while updated results showed “sustained and dose-dependent improvements” in cardiac measures.The bullish revisions followed Lexeo’s announcement that the FDA was open to a Biologics License Application (BLA) that combines data from its Phase I/II studies with new pivotal data to support accelerated approval. The agency also agreed to assess LVMI improvements earlier than 12 months.Interim results from the ongoing LX2006 trials showed encouraging efficacy, with participants who had abnormal heart mass at baseline achieving an average 18% reduction in LVMI at six months and 23% at 12 months, well above the FDA’s 10% improvement threshold.&nbsp;Neurological function also improved as measured by patients' scores on the modified Friedreich Ataxia Rating Scale (mFARS) and reductions in cardiac biomarkers, including troponin I and lateral wall thickness. The therapy was well tolerated, with no serious adverse events. The company plans to initiate the pivotal study in the first half of 2026, pending completion of final protocol and manufacturing comparability reviews.LX2006 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations, among others, and is part of the FDA’s CMC Development and Readiness Pilot (CDRP) program. The company expects the therapy to advance into its pivotal stage within the next year and believes the new framework could bring approval two years earlier than previously projected.On Stocktwits, retail sentiment for Lexeo was ‘extremely bullish’ amid a 6,200% surge in 24-hour message volume.One user called the FDA update a major win but warned of a dilution risk, noting that Lexeo’s $75 million shelf registration and recent $80 million private placement could lead to a share sale if the stock continues to rise. They said it’s a typical biotech setup with big news, big move, then dilution.<stembedurl>https://stocktwits.com/Jamesnewbie/message/631275401</stembedurl>Another user took a more upbeat tone, suggesting a rapid rally ahead, stating that a swift move to $20 could be on the way.&nbsp;<stembedurl>https://stocktwits.com/kpop1/message/631309344</stembedurl><a href="https://stocktwits.com/symbol/LXEO">Lexeo’s stock</a> has risen 27% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo’s stock (LXEO) has risen 27% so far in 2025. (Photo credit: Getty Images)

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Analysts raised price targets and boosted approval odds after the FDA signaled support for a faster review process, citing strong safety and efficacy data in early trials of Lexeo’s treatment for Friedreich’s ataxia–related heart disease.

Equity

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the first half of 2026, pending finalization of the study protocol.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-progress-fda-discussions">data</a> from the planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy, the company stated after discussions with the agency.Lexeo will submit enhanced manufacturing comparability data and meet an additional nonclinical requirement before the initiation of the planned pivotal study to enable pooling, the company added.Lexeo is continuing to engage with the agency regarding the protocol of the pivotal study, it stated, adding that it believes this regulatory feedback has the potential to reduce the size and duration of the planned pivotal study. The company is also optimistic that the feedback may accelerate the overall timeline to an application submission.Updated interim clinical data from both ongoing Phase I/II studies of LX2006 show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich’s ataxia, the company said.FA cardiomyopathy is the leading cause of death in individuals with Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disorder causing progressive damage to the nervous system, leading to impaired balance, muscle coordination, and sensory loss, often beginning in childhood. It is estimated to affect approximately 5,000 people in the U.S.Shares of the company rallied 24% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LXEO">LXEO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1368/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_9_19_18_AM_png_3d23b7c692.webp" alt="LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1368" height="120"><figcaption>LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>LXEO stock has risen 22% this year and but fallen by approximately 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-slashes-workforce-at-its-us-wegovy-manufacturing-plant/ch6PBqJR3WD">Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy. 

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of clinical-stage genetic medicine company Lexeo Therapeutics, Inc. soared over 50% on Monday, marking their best day on record. The rally extended into after-hours trading following the company's latest quarterly results, which largely pleased investors.Lexeo specializes in therapies for hereditary and acquired diseases, with a focus on genetically defined cardiovascular conditions and a subset of Alzheimer's disease.&nbsp;Its pipeline includes LX2006 for treating Friedreich's ataxia cardiomyopathy and LX1001 for APOE4 homozygous Alzheimer's patients.According to Stocktwits data, the company reported an adjusted fourth-quarter loss of $0.78 per share, beating expectations for a $0.81 loss. The early-stage biotech firm is still in a pre-revenue stage.CEO R. Nolan Townsend highlighted regulatory progress on LX2006, noting ongoing collaboration with the FDA for an accelerated approval pathway.&nbsp;He also announced promising early safety data for LX2020, a treatment for arrhythmogenic cardiomyopathy (PKP2-ACM).&nbsp;The company expects to share additional clinical updates later in 2025, with the second cohort of a Phase 1/2 trial now fully enrolled.Despite the stock's sharp rally, Leerink lowered its price target from $19 to $18, which still implies a potential fourfold gain from current levels.&nbsp;The research firm remains bullish, citing positive registrational design elements in the LX2006 pivotal trial and interim data for LX2020.Lexeo ended 2024 with $128.5 million in cash and investments, which management believes will sustain operations into 2027.On Stocktwits, Lexeo's following surged 13% — the largest jump among biotech stocks.&nbsp;The stock, however, remains down over 39% year-to-date, with short interest creeping up from 6.2% to 7.3%.Traders on Stocktwits are watching technical patterns closely.&nbsp;"Nice breakout. I could see this running for a while," one user noted.<stembedurl>https://stocktwits.com/Sillyspuh/message/609105298</stembedurl>Another speculated that a cup-and-handle formation was forming.<stembedurl>https://stocktwits.com/Marcobucks/message/609063542</stembedurl>According to Koyfin, seven Wall Street analysts cover Lexeo. Four rate it a 'buy,' while three assign a 'strong buy' or equivalent rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.  

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ('Satellos' or the 'Company'), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene...

Buy Rating Affirmed for Lexeo Therapeutics Amid Promising Clinical Trial Results for FA-CM Treatment

Geulah Livshits, an analyst from Chardan Capital, reiterated the Buy rating on Lexeo Therapeutics, Inc. (LXEO Research Report). The associated pr...

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor...

Lexeo Therapeutics expects cash to fund operations into 2027

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$8.58
Prev Close	$8.50
Open	$8.73
Dividend Yield	0.00%
50-Day Moving Average	$5.64
Beta	1.92
Avg. Volume	767,846.10
PE Ratio	-2.61

52-Week High	$11.72
52-Week Low	$1.45
Market Capitalization	$459.01M
EPS (Annual)	-$3.09
Price to Book	3.32
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXEO News

LXEOLexeo Therapeutics Inc.